While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...
Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...
Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...
AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.
Reduced demand from international markets and increased regulatory complexity are among the challenges that tariffs are ...
Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...
The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...
Metsera said the Phase III trial should be initiated by the end of 2025. Image credit: Alones / Shutterstock.com. Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback